Design and rationale for a randomized, open-label, parallel clinical trial evaluating major adverse cardiovascular events (pharmacological treatment versus diet control) in patients with high-normal blood pressure: the PRINT-TAHA9 trial.
Adverse events
Cardiovascular outcome
High-normal blood pressure
Intensive blood pressure control
Major adverse cardiovascular events
Prehypertension
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
received:
10
05
2024
accepted:
21
08
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
26
8
2024
Statut:
epublish
Résumé
The distinction between normal and high blood pressure remains a debated topic, with varying guidelines on when to start medication. Contemporary guidelines advocate for the initiation of antihypertensive therapy in individuals who present with high-normal blood pressure, particularly those exhibiting elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores. Despite these recommendations, there is a notable lack of direct evidence supporting the efficacy of treating high-normal blood pressure to prevent major adverse cardiovascular events (MACE). The PRINT-TAHA9 trial, a unicentric, randomized, open-label, controlled, parallel clinical study, seeks to explore the effects of intensive blood pressure control on MACE in participants with high-normal blood pressure. We will enroll 1620 adults aged 18 years and above with a systolic blood pressure range of 130-140 mmHg, diastolic blood pressure under 90 mmHg, and atherosclerotic cardiovascular disease (ASCVD) risk score exceeding 7.5%. The study will be executed in five distinct phases, with each phase enrolling between 300 and 400 participants. Participants will be randomly assigned to either the treatment group receiving antihypertensive medication (amlodipine/valsartan) and a low-salt/low-fat diet or to the control group receiving a similar diet. Follow-up visits are scheduled every 6 months over a 3-year period to monitor blood pressure, evaluate medication adherence, document any adverse events, and adjust the intervention as necessary. Cox proportional hazards regression analysis will be employed to examine the disparities between the two arms. Despite guidelines promoting early treatment of elevated blood pressure, the debate continues due to insufficient evidence that such interventions significantly reduce the occurrence of MACE. This trial seeks to address this critical evidence gap. The PRINT-TAHA9 trial was registered in October 2019 with the Iranian Registry of Clinical Trials (IRCT.ir) under the registration number IRCT20191002044961N1. https://irct.behdasht.gov.ir/trial/43092 .
Sections du résumé
BACKGROUND
BACKGROUND
The distinction between normal and high blood pressure remains a debated topic, with varying guidelines on when to start medication. Contemporary guidelines advocate for the initiation of antihypertensive therapy in individuals who present with high-normal blood pressure, particularly those exhibiting elevated 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores. Despite these recommendations, there is a notable lack of direct evidence supporting the efficacy of treating high-normal blood pressure to prevent major adverse cardiovascular events (MACE).
METHODS
METHODS
The PRINT-TAHA9 trial, a unicentric, randomized, open-label, controlled, parallel clinical study, seeks to explore the effects of intensive blood pressure control on MACE in participants with high-normal blood pressure. We will enroll 1620 adults aged 18 years and above with a systolic blood pressure range of 130-140 mmHg, diastolic blood pressure under 90 mmHg, and atherosclerotic cardiovascular disease (ASCVD) risk score exceeding 7.5%. The study will be executed in five distinct phases, with each phase enrolling between 300 and 400 participants. Participants will be randomly assigned to either the treatment group receiving antihypertensive medication (amlodipine/valsartan) and a low-salt/low-fat diet or to the control group receiving a similar diet. Follow-up visits are scheduled every 6 months over a 3-year period to monitor blood pressure, evaluate medication adherence, document any adverse events, and adjust the intervention as necessary. Cox proportional hazards regression analysis will be employed to examine the disparities between the two arms.
DISCUSSION
CONCLUSIONS
Despite guidelines promoting early treatment of elevated blood pressure, the debate continues due to insufficient evidence that such interventions significantly reduce the occurrence of MACE. This trial seeks to address this critical evidence gap.
TRIAL REGISTRATION
BACKGROUND
The PRINT-TAHA9 trial was registered in October 2019 with the Iranian Registry of Clinical Trials (IRCT.ir) under the registration number IRCT20191002044961N1. https://irct.behdasht.gov.ir/trial/43092 .
Identifiants
pubmed: 39187881
doi: 10.1186/s13063-024-08420-2
pii: 10.1186/s13063-024-08420-2
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Clinical Trial Protocol
Langues
eng
Sous-ensembles de citation
IM
Pagination
563Informations de copyright
© 2024. The Author(s).
Références
Carey RM, Whelton PK. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018;168(5):351–8.
doi: 10.7326/M17-3203
pubmed: 29357392
Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–104.
doi: 10.1093/eurheartj/ehy339
pubmed: 30165516
Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071.
doi: 10.1097/HJH.0000000000003480
pubmed: 37345492
Attar A, Sayadi M, Jannati M. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: a secondary analysis of the SPRINT trial. Eur J Prev Cardiol. 2019;26(3):238–45.
doi: 10.1177/2047487318800741
pubmed: 30256671
Borazjani R, Kojuri J, Abdi-Ardekani A, Izadpanah P, Dehghani P, Sayadi M, et al. Pharmacological treatment of high-normal blood pressure (prehypertension) in high-risk patients for primary prevention of cardiovascular events. J Clin Hypertens (Greenwich). 2020;22(9):1627–34.
doi: 10.1111/jch.13994
pubmed: 32815661
Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018;378(6):497–9.
doi: 10.1056/NEJMp1716193
pubmed: 29341841
Carey RM, Whelton PK. Evidence for the universal blood pressure goal of <130/80 mm Hg is strong: controversies in hypertension - pro side of the argument. Hypertension. 2020;76(5):1384–90.
doi: 10.1161/HYPERTENSIONAHA.120.14647
pubmed: 32951472
Han M, Li Q, Liu L, Zhang D, Ren Y, Zhao Y, et al. Prehypertension and risk of cardiovascular diseases: a meta-analysis of 47 cohort studies. J Hypertens. 2019;37(12):2325–32.
doi: 10.1097/HJH.0000000000002191
pubmed: 31335511
Bawazier LA, Sja’bani M, Irijanto F, Zulaela Z, Widiatmoko A, Kholiq A, et al. Association of serum uric acid, morning home blood pressure and cardiovascular risk factors in a population with previous prehypertension: a cross-sectional study. BMJ Open. 2020;10(9): e038046.
doi: 10.1136/bmjopen-2020-038046
pubmed: 32912954
pmcid: 7482459
Egan BM, Stevens-Fabry S. Prehypertension—prevalence, health risks, and management strategies. Nat Rev Cardiol. 2015;12(5):289.
doi: 10.1038/nrcardio.2015.17
pubmed: 25687779
Russell LB, Valiyeva E, Carson JL. Effects of prehypertension on admissions and deaths: a simulation. Arch Intern Med. 2004;164(19):2119–24.
doi: 10.1001/archinte.164.19.2119
pubmed: 15505125
Materson BJ, Garcia-Estrada M, Degraff SB, Preston RA. Prehypertension is real and can be associated with target organ damage. J Am Soc Hypertens. 2017;11(11):704–8.
doi: 10.1016/j.jash.2017.09.005
pubmed: 28965768
Qureshi AI, Suri MFK, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases? Stroke. 2005;36(9):1859–63.
doi: 10.1161/01.STR.0000177495.45580.f1
pubmed: 16081866
Duan W, Wu J, Liu S, Jiao Y, Zheng L, Sun Y, et al. Impact of prehypertension on the risk of major adverse cardiovascular events in a Chinese rural cohort. Am J Hypertens. 2020;33(5):465–70.
doi: 10.1093/ajh/hpaa019
pubmed: 32030405
Attar A, Nouri F, Borazjani R, Sayadi M. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: a post-hoc analysis of the SPRINT trial. PLoS ONE. 2020;15(10): e0240102.
doi: 10.1371/journal.pone.0240102
pubmed: 33002071
pmcid: 7529282
Redrup MJ, Igarashi H, Schaefgen J, Lin J, Geisler L, Ben M’Barek M, et al. Sample management: recommendation for best practices and harmonization from the Global Bioanalysis Consortium Harmonization Team. AAPS J. 2016;18(2):290–3.
doi: 10.1208/s12248-016-9869-2
pubmed: 26821803
pmcid: 4779093
Zhong B. How to calculate sample size in randomized controlled trial? J Thorac Dis. 2009;1(1):51–4.
pubmed: 22263004
pmcid: 3256489
Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
doi: 10.1001/jama.2013.281053
Soni D, Singh K, Ambalam C, Vamadevan A, Kinra S, Singh K, et al. A16184 clinical profile of acute myocardial infarction patients with and without hypertension. J Hypertens. 2018;36:e229–30.
doi: 10.1097/01.hjh.0000548938.68524.7b
Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension. 2006;47(3):410–4.
doi: 10.1161/01.HYP.0000205119.19804.08
pubmed: 16446387
Ren Y, Zuo Y, Wang A, Chen S, Tian X, Li H, et al. Diabetes modifies the association of prehypertension with cardiovascular disease and all‐cause mortality. J Clin Hypertens. 2021.
Iellamo F, Werdan K, Narkiewicz K, Rosano G, Volterrani M. Practical applications for single pill combinations in the cardiovascular continuum. Card Fail Rev. 2017;3(1):40.
doi: 10.15420/cfr.2017:5:1
pubmed: 28785474
pmcid: 5494156
Shao L, Chan P, Tomlinson B, Zhang Y, Liu Z-M. Single-pill combinations for hypertension: first line treatment for all? Curr Med Res Opin. 2019;35(1):113–5.
doi: 10.1080/03007995.2018.1541444
pubmed: 30362846
Dézsi CA, Glezer M, Karpov Y, Brzozowska-Villatte R, Farsang C. Effectiveness of perindopril/indapamide single-pill combination in uncontrolled patients with hypertension: a pooled analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO observational studies. Adv Ther. 2021;38(1):479–94.
doi: 10.1007/s12325-020-01527-3
pubmed: 33150570
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels—overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296–304.
doi: 10.1097/HJH.0000000000000379
pubmed: 25259547